Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...

  2. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  3. Drug

    Becotatug vedotin

    go.drugbank.com/drugs/DB17407
    Investigational

    MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.

  4. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  5. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb).

  6. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  7. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared

    Mixtures: Nonivamid + Nicoboxil Zentiva 4 mg/g + 25 mg/g Salbe
  8. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  9. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which

  10. Drug

    Temelimab

    go.drugbank.com/drugs/DB15634
    Investigational

    Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).